Produces dried cannabis for medical and recreational use. Manufactures cannabis extracts for various applications. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 98% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $32.9M a year. A small number, but proof the product has real buyers.
There is $52.0M in the vault; even if every debt were paid off, $41.8M would remain.
A loss of $9.8M against $32.9M in annual sales.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 5,251.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.